There is no difference in safety and efficacy mechanical thrombectomy alone or mechanical thrombectomy with tirofiban for patients undergoing treatment of large vessel occlusion and underlying intracranial atherosclerosis

• DOI: 10.1016/j.inat.2021.101383
• Publication Date: 2021-09-23T00:05:35Z
• Authors: Hari Movva; Rani Rabah; Wondwossen Tekle; Laurie Preston; Hari Kotta; Ameer E Hassan
• Keywords: Tirofiban; Demographics; Stroke

Mechanical thrombectomy (MT) is a widely proven method to treat acute ischemic stroke (AIS) during mechanical and stenting angioplasty topic discussed till this day regarding safety efficacy. However, intravenous glycoprotein IIb/IIIa agents such as Tirofiban have become more common thing. We report the analysis of all AIS patients treated with + MT vs. alone. Using prospectively collected endovascular database at CSC between 2013 2019, workflow, outcomes were recorded. Patients are given undergoing alone analyzed obtain baseline demographics, modified Ranking Scale (mRS) discharge, 90 days follow up, pre post thrombolysis in cerebral infarction (TICI), mortality rate, hemorrhage rates. There was total 169 study period (average age 68.18 ± 14, 41.42% female). Analysis 36 from group 69.25 14.18, 27.77% female), 133 performed 67.89 13.99, 45.11%), see Table 3 for characteristics outcomes. Four (11.11%) had symptomatic versus fourteen (10.53%) (p = .919). no significant difference two groups .622). addition does not increase risk or mortality. More extensive studies warranted prove efficacy tirofiban tandem lesions.